All News

Found 1,880 articles

• Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome

  11/30/2020

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for

• Poxel to Host Virtual NASH Investor Event with Leading Experts on December 14, 2020

  11/30/2020

  NASH key opinion leaders and Poxel management will discuss the Company’s two Phase 2 NASH programs, PXL770, a direct adenosine monophosphate-activated protein kinase (AMPK) activator, and PXL065, deuterium-stabilized R-pioglitazone

• Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

  11/25/2020

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present at th

• Reata Provides Update on Omaveloxolone Program for Patients with Friedreich’s Ataxia

  11/24/2020

  Reata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration completed its internal review of the Baseline-Controlled Study results of omaveloxolone for the treatment of patients with Friedreich’s ataxia and concluded that the results do not strengthen the results of Part 2 of the MOXIe study.

• vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital

  11/24/2020

  vTv Therapeutics Inc. announced it has entered into a common stock purchase agreement for up to $47 million with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor.

• Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering

  11/24/2020

  Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the closing of its previously announced registered direct offering of 2,844,446 of its American Depositary Shares ("ADSs"),

• Minovia Therapeutics Announces Manufacturing Partnership with BioSpherix and Appoints David O’Donnell as Global Head of Manufacturing and Supply Chain

  11/23/2020

  Minovia Therapeutics, a clinical-stage company focused on the development of cell-based Mitochondrial Augmentation Therapy (MAT) to treat mitochondrial diseases, announced today a major expansion of its physical and organizational cGMP US manufacturing capability through a collaboration with BioSpherix, a specialized cell therapy equipment manufacturer

• Novel Antioxidant Seen as an Effective Strategy for Peripheral Artery Disease

  11/20/2020

  Researchers within the School of Health and Kinesiology at the University of Nebraska at Omaha (UNO) have found that a novel antioxidant can provide a number of health benefits for individuals with peripheral artery disease.

• Stealth BioTherapeutics Announces $3.2 Million Registered Direct Offering

  11/20/2020

   Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has entered into securities purchase agreements with several institutional investors to purchase 2,844,446 of its American Depositary Shares ("ADSs")

• Poxel Provides Update on Metavant Partnership with Imeglimin

  11/20/2020

  Metavant will actively explore options for a potential out-licensing of Imeglimin rights for a period of 60 days; Metavant intends to return Imeglimin rights to Poxel if they are unable to reach an agreement on material terms within this period

• Mitochondrial-Targeted Antioxidant Protects Genomes Against DNA Damage in Exercising Humans

  11/19/2020

  Healthy male participants who take a novel antioxidant that specifically targets the powerhouse of the cells, mitochondria, sees attenuation in exercise induced mitochondria DNA (mtDNA) damage in lymphocytes and muscle.

• CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference

  11/19/2020

  CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the Piper Sandler 32 nd Annual Healthcare Conference, being held virtually on December 1 - 3, 2020. This presentation will be available on demand for registered attendees. Abo

• Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China

  11/17/2020

  Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with GenScience Pharmaceuticals - a wholly-owned subsidiary of Changchun High-Tech Industry Co., Ltd.

• 

  Clinical Catch-Up: November 9-13

  11/16/2020

  It was a particularly busy week for clinical trial updates, mostly because of several virtual conferences, including the virtual American Heart Association Scientific Sessions 2020 and The Society for Immunotherapy of Cancer’s Annual Meetings. Here's a look.

• Amylyx Pharmaceuticals Announces FDA Granted Orphan Drug Designation for AMX0035 for the Treatment of Wolfram Syndrome

  11/16/2020

  Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035 for the treatment of Wolfram syndrome. “There is a critical unmet need for people living with Wolfram syndrome, a r

• Seal Rock Therapeutics Presents Data Highlighting Superior Efficacy of ASK1 Inhibitor, SRT-015, to Selonsertib for NASH

  11/16/2020

  Seal Rock Therapeutics, Inc., a late-preclinical stage biotechnology company developing first-in-class and best-in-class treatments for severe liver diseases with limited or no available therapies, today announced the presentation of data demonstrating comparative efficacy and pharmacokinetic findings on SRT-015, a second-generation,

• Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting® 2020

  11/16/2020

  Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting ® 2020 Data support potential utility for treatment of NASH Analysis of results from the Phase 1b study of PXL065 (deuterium-stabilized R-pioglitazone) predicts efficacy at 15 mg once-daily is equivalent to 45 mg Actos ®* , with little to no PPARg-related side effects, such as weight gain

• CohBar Reports Third Quarter 2020 Financial Results and Provides Business UpdateCompany to host conference call and webcast at 5:00 p.m. ET

  11/16/2020

  CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the third quarter ended September 30, 2020.

• Madrigal Pharmaceuticals will make an oral presentation today at 4:30 PM ET at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting

  11/13/2020

  Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™ , AASLD Product Theater on Friday , November 13 , 2020 , at 4:30 PM ET.

• Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

  11/12/2020

  - Company nominates OPA1 as the next preclinical target for its proprietary TANGO approach to treating the underlying cause of severe genetic diseases – - OPA1 protein deficiency is the leading cause of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder –